Neopharm
Empowering Life Sciences with Innovative Analytical Services

Neopharm has been a leader in the life sciences industry for more than three decades. They continuously set benchmarks through strategic enhancements, whether it’s through strategic acquisitions or the establishment of Neopharm Life Sciences, a new business unit that caters to the growing demands of the biopharmaceutical sector. This Canadian-based company has solidified its position as an industry leader.

Neopharm’s Holistic Approach to Life Sciences

Headquartered in Blainville, Québec, Canada, Neopharm is a renowned provider of GMP analytical testing services. With state-of-the-art facilities located in North America and a wide range of services, the company is a trusted partner and is subject to frequent inspections by regulatory agencies such as the U.S. FDA and Health Canada.

The recent announcement of the unification of Neopharm Labs, Averica Discovery Services, and MS Pharma under the consolidated entity of Neopharm is a significant milestone. This strategic alignment marks a new era of expertise and comprehensive analytical services for the life sciences industry.

The integration includes Neopharm Boston, formerly known as Averica Discovery Services, which specializes in small molecule analysis and purification. Neopharm Boston plays a vital role in supporting chemistry teams during the transition from drug discovery to development. Their chromatography-based services enrich Neopharm’s capabilities, encompassing method development, impurity isolation, scalable small molecule purification, and custom assay development.

Completing the triad is Neopharm Laval, formerly known as MS Pharma, a reputable pharmaceutical chemistry and microbiology contract laboratory established in 2008. Neopharm Laval’s expertise in quality control, validation, and stability services spans the pharmaceutical, cosmetics, and nutraceutical industries. Yvan Côté, President and General Manager at Neopharm, expresses excitement about the acquisition, highlighting the opportunity to expand services to the cosmeceutical and nutraceutical markets, increase geographic coverage, and strengthen the company’s market presence. “This addition bolsters Neopharm’s ability to serve diverse sectors with precision and excellence”.

Unified Strengths for Unrivaled Excellence

Neopharm’s mission is clear — to stand alongside life sciences partners, ensuring the quality of their products through proven analytical services. Leveraging collective expertise, cutting-edge technologies, and an unwavering commitment to excellence, the company aspires not only to lead the industry but also to be the employer of choice, attracting and nurturing top talent to continually propel capabilities forward.
Neopharm visual transformation symbolizes a commitment to revolutionizing the landscape of analytical services. Neopharm aims to inspire a brighter future for the life sciences industry, supporting its partners in the product development journey.

Neopharm Life Sciences - A Hub for Biotech Innovation

The recently inaugurated Life Sciences business unit brings a comprehensive suite of services to the table, fortified by a team of highly skilled scientists and industry experts proficient in various analytical technologies. Biological testing solutions provided by Neopharm Life Sciences provide accurate, reliable, and prompt biological testing solutions, supporting clients through every stage of biopharmaceutical development. Services include ELISA assays, enzymatic activity tests, SDS-Page tests, LC/MS quantitative analyses, peptide mapping, nucleic acid amplification tests, genetic sequencing, cell-based assays, and more.

In the realm of biologicals, vaccines, and gene- and cell therapy products, Neopharm Life Sciences stands out with diversified offerings. Clients benefit from comprehensive testing platforms tailored to each case, ensuring successful ad-hoc investigations. Beyond testing, Neopharm Life Sciences provides services to isolate and purify foreign substances found in drug substances or products, reinforcing the company’s position as a trusted partner in the pharmaceutical industry for over 30 years.

In Conversation with Yvan Côté: President and General Manager of Neopharm

In an exclusive interview, Yvan Côté sheds light on Neopharm’s journey, emphasizing the company’s expansion and the establishment of Neopharm Life Sciences. Côté discusses the acquisition of MS Pharma, detailing how it contributes to the company’s growth strategy and service diversification. He highlights the challenges faced by the biopharmaceutical industry and the pivotal role Neopharm plays in providing expertise, access to technology, and personalized solutions.

“As Neopharm continues to evolve, the company’s commitment to empowering the life sciences industry through innovative analytical services remains unwavering. Our strategic integration and expansion pave the way for a transformative journey, positioning Neopharm as a driving force in shaping the future of the life sciences landscape”. Côté concluded.